BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31989379)

  • 21. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
    de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary management of the axilla in breast cancer.
    Nurudeen S; Hunt KK
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):823-831. PubMed ID: 30843891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.
    Huang TW; Kuo KN; Chen KH; Chen C; Hou WH; Lee WH; Chao TY; Tsai JT; Su CM; Huang MT; Tam KW
    Int J Surg; 2016 Oct; 34():73-80. PubMed ID: 27562691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).
    van Roozendaal LM; Vane MLG; van Dalen T; van der Hage JA; Strobbe LJA; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; Van de Vijver KKBT; de Vries J; Westenberg AH; Kessels AGH; de Wilt JHW; Smidt ML
    BMC Cancer; 2017 Jul; 17(1):459. PubMed ID: 28668073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
    Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
    Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center.
    Garcia-Etienne CA; Ferrari A; Della Valle A; Lucioni M; Ferraris E; Di Giulio G; Squillace L; Bonzano E; Lasagna A; Rizzo G; Tancredi R; Scotti Foglieni A; Dionigi F; Grasso M; Arbustini E; Cavenaghi G; Pedrazzoli P; Filippi AR; Dionigi P; Sgarella A
    Eur J Surg Oncol; 2020 Jan; 46(1):15-23. PubMed ID: 31445768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
    Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
    Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial.
    Roy P; Leizorovicz A; Villet R; Mercier C; Bobin JY
    Breast Cancer Res Treat; 2018 Jul; 170(2):303-312. PubMed ID: 29526019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
    Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolution of the sentinel node procedure in the treatment of breast cancer.
    Tvedskov TF
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can Complete Axillary Node Dissection Be Safely Omitted in Patients with Early Breast Cancer When the Sentinel Node Biopsy Is Positive for Malignancy? An Update for Clinical Practice.
    Gera R; Kasem A; Mokbel K
    In Vivo; 2018; 32(6):1301-1307. PubMed ID: 30348682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in Regional Nodal Management of Breast Cancer Patients with Low Nodal Burden.
    Raber BM; Lin H; Shen Y; Shaitelman SF; Bedrosian I
    Ann Surg Oncol; 2019 Dec; 26(13):4346-4354. PubMed ID: 31605340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of a predictive model of axillary lymph node status in patients with sentinel node metastasis from breast cancer. A retrospective cohort study.
    Vieni S; Graceffa G; La Mendola R; Latteri S; Cordova A; Latteri MA; Cipolla C
    Int J Surg; 2016 Nov; 35():58-63. PubMed ID: 27633450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
    Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.